EOLSEvolus Inc
$5.63
$0.33
(5.54%)
EarningsAug 4
Mkt Cap$392.49M
Vol810,288.00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the companys common stock to 38 newly hired non-executive...
Business Wire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics PR Newswire RENO, Nev., July 9, 2026 Issued on behalf of Conexeu Sciences Inc.Conexeu...
PR Newswire
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and...
Business Wire
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
Notable Wednesday Option Activity: EOLS, PRCH, ZS
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Evolus Inc (Symbol: EOLS), where a total volume of 4,005 contracts has been traded thus far today, a contract volume which is representative of approximately 400...
Nasdaq News: Markets
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK, May 22, 2026 Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ...
PR Newswire
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a...
Business Wire
Evolus Announces Commercial Launch of Estyme Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme (pronounced...
Business Wire
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evolus Q1 Earnings Call Highlights
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest EOLS News
ViewEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
PR Newswire
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality
Business Wire
Advertisement|Remove ads.